Walethmade%25252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252520bromide

# Walethmade%25252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252520bromide ## Overview Walethmade%25252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252520bromide is a synthetic opioid analgesic. It is a potent mu-opioid receptor agonist. ## Primary Indications Management of moderate to severe pain. ## Adult Dosing Dosing is highly individualized based on pain severity, patient tolerance, and prior opioid exposure. A common starting dose is 25 mcg/hour transdermal patch, applied every 72 hours. Titration is typically done in increments of 25 mcg/hour every 3 days. ## Pediatric Dosing There is no established pediatric dosing for Walethmade%25252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252520bromide. ## Dose Adjustments * **Hepatic Impairment:** Use with caution. Dosing may need to be reduced. * **Renal Impairment:** Use with caution. Dosing may need to be reduced. ## Contraindications * Hypersensitivity to Walethmade%25252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252520bromide or other opioids. * Acute or severe asthma or other conditions where bronchodilation is dangerous. * Gastrointestinal obstruction or ileus. * Concurrent use with MAO inhibitors or within 14 days of their discontinuation. ## Adverse Effects Common: Constipation, nausea, somnolence, dizziness, pruritus, vomiting, dry mouth, headache, fatigue, sweating. Serious: Respiratory depression, CNS depression, opioid-induced hyperalgesia, severe constipation leading to bowel obstruction, adrenal insufficiency, hypogonadism, serotonin syndrome (with co-administration of serotonergic agents). ## Key Drug Interactions * **CNS Depressants (e.g., benzodiazepines, alcohol, sedatives):** Increased risk of profound sedation, respiratory depression, coma, and death. * **MAO Inhibitors:** Contraindicated. * **Serotonergic Agents (e.g., SSRIs, SNRIs, triptans):** Increased risk of serotonin syndrome. * **CYP3A4 Inhibitors (e.g., ketoconazole, itraconazole):** May increase Walethmade%25252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252520bromide concentrations and effects. * **CYP3A4 Inducers (e.g., rifampin, carbamazepine):** May decrease Walethmade%25252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252520bromide concentrations and effects. ## Monitoring * Pain level and efficacy of treatment. * Signs and symptoms of opioid withdrawal. * Respiratory rate and depth. * Sedation level. * Bowel function (for constipation). * Electrolytes and renal/hepatic function periodically, especially in patients with impaired function or on long-term therapy. ## Clinical Pearls * Transdermal application results in gradual absorption and steady-state plasma concentrations. The full analgesic effect may not be achieved for up to 72 hours after initial application. * Discontinue the previous opioid regimen gradually when initiating Walethmade%25252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252520bromide. * Monitor closely for respiratory depression, especially during initiation and dose titration, or when co-administered with other CNS depressants. * Educate patients on proper patch application, disposal, and avoidance of heat sources (e.g., heating pads, hot tubs) to the application site, as this can increase drug absorption and risk of overdose. * Do not cut or divide patches. *** *Disclaimer: This information is intended for clinical use and is not a substitute for professional medical advice. Always consult the most current prescribing information and relevant clinical guidelines before making any treatment decisions. Dosing and safety information can change.*